Litigation Details for Cipla Ltd. v. Amgen Inc. (D. Del. 2019)
✉ Email this page to a colleague
Cipla Ltd. v. Amgen Inc. (D. Del. 2019)
| Docket | ⤷ Try a Trial | Date Filed | 2019-01-08 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 15:1 Antitrust Litigation | Assigned To | Leonard Philip Stark |
| Jury Demand | Plaintiff | Referred To | |
| Patents | 9,375,405 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Cipla Ltd. v. Amgen Inc.
The small molecule drug covered by the patent cited in this case is ⤷ Try a Trial .
Details for Cipla Ltd. v. Amgen Inc. (D. Del. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2019-03-13 | 142 | Redacted Document | embodied the claimed invention of U.S. Patent No. 9,375,405 (the “’405 Patent”). 55. The purpose… ’405 Patent to exclude the sale of Cinacalcet Products falling outside the scope of the patent. … 65. The ’405 Patent is currently unenforceable by reason of the patent misuse identi- fied in…Teva Products are outside the scope of the ’405 Patent. 14. By not later than December 29,…compound called etelcalcetide on which Amgen holds a patent. 46. Between 2004, when FDA approved | External link to document |
| 2019-02-01 | 27 | Redacted Document | side the scope of United States Patent No. 9,375,405 B2 (the “’405 Patent”). 12. As of December…INFRINGEMENT of claims 1-6 and 8-20 of the ’405 patent is hereby entered in favor of Watson and against | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
